One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability.Iñigo Garamendi-Ruíz, María Eugenia García-García, +17 authors Ainhoa Marinas-AlejoEpileptic disorders : international epilepsy…2016Perampanel, a non-competitive antagonist of the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors, is the most recent antiepileptic drug available in Spain, marketed in January 2014. It… (More)